Evenity (Romosozumab) for Geriatric Patients (65+): Transition to Adult Care

What Is Romosozumab and Why Does It Matter in Geriatric Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption. No other approved osteoporosis agent does both at once, making it the most potent tool in the geriatric fracture-prevention toolkit.

Osteoporosis affects approximately 10.2 million Americans aged 50 and older, with prevalence rising sharply after age 65. Bone density loss accelerates in the decade after menopause and continues at roughly 0.5 to 1% per year throughout older adulthood. Hip fractures in adults over 70 carry a 1-year mortality rate of approximately 20 to 30%, meaning that fracture prevention in this age group is a direct survival intervention, not merely a quality-of-life issue.

Who Qualifies as High Fracture Risk?

The Endocrine Society and the American Association of Clinical Endocrinologists define high fracture risk as a 10-year major osteoporotic fracture probability at or above 20% by FRAX, a T-score at or below -2.5, or a prior low-trauma vertebral or hip fracture. AACE guidelines specifically recommend anabolic-first sequencing (romosozumab or teriparatide before antiresorptive therapy) for patients at very high risk. In practice, most geriatric patients presenting with a fragility fracture and a T-score at or below -2.5 meet criteria for romosozumab.

How Romosozumab Differs from Older Anabolic Agents

Teriparatide (Forteo) and abaloparatide (Tymlos) are parathyroid hormone-related agents that work primarily by stimulating bone formation. Romosozumab adds the antiresorptive dimension, which produces faster and larger BMD gains. In the FRAME trial (N=7,180), romosozumab increased lumbar spine BMD by 13.3% at 12 months compared with 0% in the placebo group. The FRAME trial, published in the New England Journal of Medicine, demonstrated a 73% reduction in new vertebral fractures at 12 months (P<0.001).

The FRAME and ARCH Trials: Evidence Grounding Geriatric Use

Understanding both key trials is essential for any clinician coordinating romosozumab care in older adults.

FRAME Trial (Romosozumab vs. Placebo)

FRAME enrolled 7,180 postmenopausal women with a mean age of 70.9 years and a lumbar spine or total hip T-score between -2.5 and -3.5. Participants received 210 mg romosozumab or placebo monthly for 12 months, then all transitioned to denosumab 60 mg every 6 months for an additional 12 months.

Key results at 12 months (romosozumab vs. Placebo):

• New vertebral fractures: 0.5% vs. 1.8% (73% relative risk reduction)
• Clinical fractures: 1.6% vs. 2.1% (36% risk reduction)
• Lumbar spine BMD gain: 13.3% vs. 0%
• Total hip BMD gain: 6.9% vs. 0%

At 24 months, after both groups had transitioned to denosumab, the vertebral fracture advantage persisted with a 75% relative risk reduction in the romosozumab-to-denosumab group versus placebo-to-denosumab. This finding underscores that gains made during the anabolic phase are preserved and extended when proper sequencing follows.

ARCH Trial (Romosozumab vs. Alendronate)

ARCH enrolled 4,093 postmenopausal women at high fracture risk, many of whom had prevalent vertebral fractures. The mean age was 74.3 years. Participants received romosozumab 210 mg monthly for 12 months followed by alendronate 70 mg weekly, compared with alendronate alone throughout.

Results published in the New England Journal of Medicine showed that the romosozumab-then-alendronate group had 48% fewer new vertebral fractures, 27% fewer major osteoporotic fractures, and 38% fewer hip fractures compared with the alendronate-alone group at a median of 33 months. The hip fracture reduction (38%) is particularly relevant in geriatric care, where hip fractures drive the highest morbidity and mortality.

Cardiovascular Signal in ARCH

In ARCH, serious cardiovascular events (cardiac ischemia or cerebrovascular events) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group during the 12-month active treatment phase. This difference prompted the FDA to add a boxed warning. The FDA label states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding 12 months. No imbalance was seen in FRAME, where the comparator was placebo rather than an active cardiovascular-protective agent. Clinicians should interpret the ARCH cardiovascular signal as a relative contraindication signal rather than absolute evidence of drug causality, while still applying the FDA warning strictly.

Cardiovascular Risk Assessment Before Starting Romosozumab in Older Adults

Geriatric patients carry a higher baseline burden of cardiovascular disease than younger adults. A 75-year-old woman has a substantially higher 10-year ASCVD risk than a 55-year-old, making pre-treatment cardiac screening non-negotiable.

Minimum Pre-Treatment Cardiovascular Checklist

Before prescribing romosozumab to any patient aged 65 or older, the prescribing team should document:

1. Date of most recent MI or stroke (contraindicated within 12 months)
2. Current antiplatelet or anticoagulant regimen
3. NYHA heart failure classification
4. Most recent ECG or echocardiogram if symptomatic
5. 10-year ASCVD risk score

Patients with an ASCVD risk above 20% or known atherosclerotic cardiovascular disease should be co-managed with cardiology before starting romosozumab. The American Heart Association recommends that clinicians assess absolute ASCVD risk prior to any therapy that carries a potential cardiovascular signal.

Monitoring During the 12-Month Course

No specific cardiac biomarker monitoring is required in the FDA label. In clinical practice, a reasonable approach is to ask about new chest pain, dyspnea, or neurological symptoms at every monthly injection visit. Any new cardiac event during the 12-month course warrants immediate discontinuation and cardiology referral.

Renal Function and Romosozumab in Geriatric Patients

Kidney function declines with age. An 80-year-old with a serum creatinine of 1.0 mg/dL may have an eGFR well below 60 mL/min/1.73m², meaning normal-appearing creatinine values routinely mask moderate-to-severe renal impairment in this population.

Romosozumab pharmacokinetics are not significantly altered in mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73m²), according to the FDA-approved label. However, the label states that the drug has not been studied adequately in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or those on dialysis, and use in those groups is not recommended.

Practical Renal Screening Steps

• Obtain a baseline comprehensive metabolic panel, including serum creatinine and eGFR, before the first injection.
• Use the CKD-EPI 2021 equation (not Cockcroft-Gault) for eGFR estimation in older adults per current nephrology guidance.
• Recheck eGFR at month 6 if baseline is between 30 and 45 mL/min/1.73m².
• Verify serum calcium is within normal range before each injection cycle; romosozumab can cause hypocalcemia, which is more dangerous in patients already on loop diuretics.

Initiating Romosozumab: Practical Steps for Geriatric Patients

Dose and Administration

The approved dose is 210 mg delivered as two separate 105 mg subcutaneous injections given consecutively at the same visit, once monthly for 12 months. Injections may be given in the abdomen, thigh, or outer upper arm. Sites should be rotated. Patients should receive adequate calcium (1,000 to 1,200 mg daily from diet plus supplements) and vitamin D (800 to 1,000 IU daily) throughout the course, per Endocrine Society Clinical Practice Guidelines on osteoporosis.

Self-Administration Versus Clinic Administration

Romosozumab is generally administered in a clinical setting because two injections must be given consecutively. Some health systems train patients or caregivers in home injection technique. For older adults with limited mobility or transportation barriers, home administration can improve adherence. Every missed monthly dose extends the time to the mandatory antiresorptive transition and risks partial loss of the anabolic window.

Baseline DXA and Laboratory Studies

Before the first injection, obtain:

• DXA of lumbar spine and bilateral hips (T-score at each site)
• Serum 25-hydroxyvitamin D (target 30 ng/mL or above)
• Serum calcium, albumin (to calculate corrected calcium)
• Comprehensive metabolic panel (eGFR, hepatic function)
• FRAX score with BMD
• Lateral thoracic and lumbar spine imaging if vertebral fracture status is unknown

A repeat DXA is recommended at the end of the 12-month course to document BMD response and to establish a baseline for antiresorptive monitoring.

The Transition Plan: What Happens After Month 12?

This is the most clinically important section for geriatric care teams. Romosozumab's anabolic effect is time-limited. When the drug is stopped without transitioning to an antiresorptive agent, bone density falls rapidly. A post-hoc analysis of FRAME data showed that patients who discontinued romosozumab without subsequent denosumab lost approximately half of the vertebral spine BMD gain within 12 months. That reversal is unacceptable in a 75-year-old who started with a T-score of -3.0.

Choosing the Right Antiresorptive Agent

The table below summarizes the sequencing decision framework for geriatric patients completing romosozumab:

| Patient Profile | Preferred Next Agent | Rationale | |---|---|---| | No prior bisphosphonate, eGFR >35, no ONJ risk | Alendronate 70 mg weekly or zoledronic acid 5 mg IV annually | ARCH trial shows hip fracture reduction; oral option improves adherence | | Prior alendronate failure or GI intolerance | Zoledronic acid 5 mg IV annually | Bypasses GI tract; single annual infusion improves adherence | | Very high re-fracture risk, T-score still <-2.5 after romosozumab | Denosumab 60 mg SC every 6 months | FRAME extension used denosumab; potent ongoing suppression of resorption | | Severe renal impairment (eGFR <35) | Denosumab (renal dose adjustment not required) | Bisphosphonates accumulate in bone and are contraindicated in severe CKD | | High fall risk, frail, limited GI tolerability | Denosumab | No food/position restrictions; SC injection every 6 months |

If denosumab is chosen as the sequencing agent, the care team must commit to indefinite therapy or plan a bridging bisphosphonate before stopping denosumab, because abrupt denosumab discontinuation causes rapid bone loss and rebound vertebral fractures. A 2019 systematic review in the Journal of Bone and Mineral Research documented a vertebral fracture rate of up to 7.1% within 7 to 24 months of stopping denosumab without bridging therapy.

Timing the Transition

The antiresorptive agent should be started the month after the 12th romosozumab injection, with no gap. For zoledronic acid, the infusion should be scheduled during the same clinic appointment as the final romosozumab injection if logistically possible, or within 30 days. For oral alendronate, the first weekly dose begins the week following the last injection.

Monitoring After Transition

• DXA at 12 to 24 months after starting the antiresorptive agent
• Serum bone turnover markers (P1NP and CTX) can assess antiresorptive adequacy at 3 to 6 months post-transition
• Annual fracture risk reassessment using updated FRAX with current BMD values

Fall Prevention and Functional Assessment in the Geriatric Context

Romosozumab reduces skeletal fragility, but bone strength is only one contributor to fracture risk in older adults. A 70-year-old with a healthy T-score can still fracture a hip in a ground-level fall if they have impaired gait, visual deficits, or polypharmacy-related orthostatic hypotension.

Integrated Fracture Prevention Beyond Pharmacotherapy

Every geriatric patient on romosozumab should be simultaneously enrolled in a multicomponent fall-prevention program. The U.S. Preventive Services Task Force recommends exercise interventions to prevent falls in community-dwelling adults aged 65 and older at increased fall risk. Balance training, strength training, and home hazard modification each reduce fall incidence independently of bone density.

Additional interventions to address at each visit:

• Medication reconciliation targeting fall-risk drugs (benzodiazepines, anticholinergics, alpha-blockers)
• Orthostatic blood pressure measurement if the patient takes antihypertensives or diuretics
• Vision screening referral if not done in the prior 12 months
• Footwear assessment

Cognitive Function and Adherence

Mild cognitive impairment affects approximately 15 to 20% of adults over 65. A patient who cannot reliably return for monthly injections or who may mismanage calcium supplementation poses adherence risks specific to this age group. A brief cognitive screen (MoCA or Mini-Cog) at baseline helps identify patients who need caregiver involvement in the treatment plan.

Polypharmacy Considerations in Geriatric Romosozumab Patients

Older adults take a median of five or more medications. Several common drug classes interact meaningfully with romosozumab's mechanism or its required supplements.

Calcium and Vitamin D Supplementation Interactions

High-dose calcium supplements taken simultaneously with certain antibiotics (fluoroquinolones, tetracyclines) reduce antibiotic absorption. The prescribing team should advise patients to separate calcium doses from these antibiotic classes by at least 2 hours.

Vitamin D repletion is mandatory. A Cochrane review (2014) found that combined vitamin D and calcium supplementation reduced hip fracture incidence by 16% (RR 0.84, 95% CI 0.74 to 0.96) in older adults. Patients on thiazide diuretics require monitoring for hypercalcemia when supplementing calcium.

Glucocorticoid Use

Oral glucocorticoids (prednisone 5 mg daily for 3 months or longer) cause glucocorticoid-induced osteoporosis (GIOP) and markedly raise fracture risk. Romosozumab is not FDA-approved specifically for GIOP, but the American College of Rheumatology 2022 guidelines conditionally recommend anabolic therapy (teriparatide over romosozumab due to limited GIOP-specific trial data) for very high-risk GIOP patients. Clinicians should document the indication for romosozumab clearly when GIOP is a contributing factor.

Anticoagulants

Romosozumab does not require anticoagulation dose adjustment. Subcutaneous injection technique in patients on warfarin or direct oral anticoagulants (DOACs) should account for increased bruising risk; applying firm pressure at the injection site for 60 seconds after each injection reduces hematoma formation.

Care Coordination Across the Geriatric Team

Geriatric patients with osteoporosis rarely see a single provider. A 78-year-old woman on romosozumab may be managed simultaneously by her primary care physician, an endocrinologist, a cardiologist, a nephrologist, and a physical therapist. Fragmented communication is the most common reason treatment gaps occur at month 12.

Documentation Requirements for Smooth Handoffs

Every prescribing team member should ensure the following are documented in the shared medical record before initiating romosozumab:

• The planned 12-month end date for romosozumab
• The name and dose of the intended antiresorptive agent after month 12
• The provider responsible for ordering the DXA at end of course
• The provider responsible for prescribing the sequencing agent

A structured care plan note at the time of prescription initiation reduces the risk of the patient completing month 12 with no follow-up scheduled.

Role of the Bone Health Coordinator

Several academic and large community health systems have implemented dedicated bone health coordinators or fracture liaison services (FLS). A 2018 systematic review in Osteoporosis International found that FLS programs increased osteoporosis treatment rates from approximately 20% to 60 to 80% in post-fracture patients. For geriatric patients on romosozumab, an FLS coordinator can track injection adherence, schedule the transition DXA, and coordinate the antiresorptive prescription before the anabolic window closes.

Special Populations Within the Geriatric Age Group

Men With Osteoporosis

The FDA approved romosozumab for men at high fracture risk in 2020, based on a 12-month randomized trial (N=245) that showed BMD gains comparable to those in women (lumbar spine BMD increase of 12.1%). That trial, published in JAMA Internal Medicine, confirmed that the mechanism and magnitude of response in men parallels what was seen in FRAME. Men over 70 with a T-score at or below -2.5 or a fragility fracture meet criteria; workup should include testosterone levels to exclude hypogonadism as a reversible contributor.

Patients With Prior Anabolic Therapy

Current guidelines advise against using two anabolic agents consecutively. A patient who completed a full teriparatide or abaloparatide course should be transitioned to an antiresorptive for at least 12 months before romosozumab is considered. The FDA label notes that prior teriparatide use does not preclude later romosozumab; the guidance is based on mechanistic concerns rather than documented harm.

Patients With a History of Osteonecrosis of the Jaw (ONJ)

Romosozumab carries a labeled risk of ONJ, though the incidence in clinical trials was low (<0.1%). Geriatric patients with a history of dental extractions, active periodontal disease, or recent oral surgery should complete any needed dental procedures before starting romosozumab and maintain scrupulous oral hygiene throughout the course. Dental clearance should be documented in the chart.

Stopping Romosozumab Early: When Is It Appropriate?

The 12-month course should be completed unless a contraindication arises. Early discontinuation is warranted for:

1. Myocardial infarction or stroke during the treatment period (immediate stop, per FDA label)
2. Severe hypocalcemia unresponsive to supplementation
3. Atypical femoral fracture (a class effect concern across all osteoporosis agents; incidence with romosozumab is not well-characterized due to course brevity)
4. Osteonecrosis of the jaw

If romosozumab is stopped before month 12, the antiresorptive transition should still be initiated promptly to preserve whatever BMD gains have been achieved. A partial course confers partial benefit, and that benefit should not be wasted.